A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations

BACKGROUND: For patients with stage IV non-small-cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib is the standard of care. Investigating the activity and safety of osimertinib in patients with EGFR exon 18 G719X, exon 20 S768I,...

Descripción completa

Detalles Bibliográficos
Autores principales: Villaruz, L.C., Wang, X., Bertino, E.M., Gu, L., Antonia, S.J., Burns, T.F., Clarke, J., Crawford, J., Evans, T.L., Friedland, D.M., Otterson, G.A., Ready, N.E., Wozniak, A.J., Stinchcombe, T.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163152/
https://www.ncbi.nlm.nih.gov/pubmed/36905787
http://dx.doi.org/10.1016/j.esmoop.2023.101183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163152/
https://www.ncbi.nlm.nih.gov/pubmed/36905787
http://dx.doi.org/10.1016/j.esmoop.2023.101183

Ejemplares similares